Food and Drug Administration, HHS

in dogs and horses: See sponsor Nos. 000061, 000856, 059130, and 061623 in $\S510.600(c)$ of this chapter.

- (2) Approval for use of the 200 milligrams per milliliter drug for use in horses: See sponsor Nos. 000010 and 058005 in §510.600(c) of this chapter.
- (3) Approval for use of the 100 milligrams per milliliter drug in dogs and horses: See sponsor No. 000856 in \$510.600(c) of this chapter.
- (c) Conditions of use for dogs. (1) It is used for the relief of inflammatory conditions associated with the musculoskeletal system.
- (2) It is administered intravenously at a dosage level of 10 milligrams per pound of body weight daily in 3 divided doses, not to exceed 800 milligrams daily regardless of weight. Limit intravenous administration to 2 successive days. Oral medication may follow.
- (3) Federal law restricts this drug to use by or on the order of a licensed veterinarian
- (d) Conditions of use for horses. (1) It is used for the relief of inflammatory conditions associated with the musculoskeletal system.
- (2) It is administered intravenously at a dosage level of 1 to 2 grams per 1,000 pounds of body weight daily in 3 divided doses, not to exceed 4 grams daily. Limit intravenous administration to not more than 5 successive days.
- (3) Not for use in animals intended for food.
- (4) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[40 FR 13858, Mar. 27, 1975]

EDITORIAL NOTE: For FEDERAL REGISTER citations affecting \$522.1720, see the List of CFR Sections Affected, which appears in the Finding Aids section of the printed volume and at www.fdsys.gov.

§ 522.1820 Pituitary luteinizing hormone for injection.

(a) Specifications. The drug is a lyophilized pituitary extract. Each 6-milliliter vial contains an amount equivalent to 25 milligrams of standard pituitary luteinizing hormone and is reconstituted for use by addition of 5 milliliters of 0.9 percent aqueous sodium chloride solution.

- (b) Sponsor. No. 000061 in \$510.600(c) of this chapter.
- (c) Conditions of use. (1) The drug is an aid in the treatment of breeding disorders related to pituitary hypofunction in cattle, horses, swine, sheep, and dogs.
- (2) Preferably given by intravenous injection, it may be administered subcutaneously; dosage is as follows: Cattle and horses, 25 mg; swine, 5 mg; sheep, 2.5 mg, and dogs, 1.0 mg. Treatment may be repeated in 1 to 4 weeks, or as indicated.
- (3) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[40 FR 13858, Mar. 27, 1975, as amended at 52 FR 7832, Mar. 13, 1987]

§522.1850 Polysulfated glycosaminoglycan.

- (a) Specifications. (1) Each 1-milliliter (mL) ampule of solution contains 250 milligrams (mg) polysulfated glycosaminoglycan.
- (2) Each mL of solution packaged in 5-mL ampules or 20-, 30-, or 50-mL vials contains 100 mg polysulfated glycosaminoglycan.
- (b) *Sponsor*. See No. 010797 in §510.600(c) of this chapter.
- (c) Special considerations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
- (d) Conditions of use—(1) Horses—(i) Indications for use. For the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.
- (ii) Amount—(A) Intra-articular use (carpal): 250 mg once a week for 5 weeks.
- (B) Intramuscular use (carpal and hock): 500 mg every 4 days for 28 days.
 (iii) Limitations. Do not use in horses
- intended for human consumption.
- (2) Dogs—(i) Indications for use. For control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.
- (ii) Amount. 2 mg per pound of body weight by intramuscular injection twice weekly for up to 4 weeks (maximum of 8 injections).
- [72 FR 56896, Oct. 5, 2007, as amended at 74 FR 67816, Dec. 21, 2009]